432 related articles for article (PubMed ID: 3129500)
1. Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells.
de Fries RU; Golub SH
J Immunol; 1988 May; 140(10):3686-93. PubMed ID: 3129500
[TBL] [Abstract][Full Text] [Related]
2. Interferon-gamma reduces the sensitivity of cultured and fresh human tumor cells to lysis by lymphokine-activated killer cells.
de Fries RU; Golub SH
Nat Immun Cell Growth Regul; 1988; 7(2):65-76. PubMed ID: 3137461
[TBL] [Abstract][Full Text] [Related]
3. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
4. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
Blanchard DK; Djeu JY
J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
[TBL] [Abstract][Full Text] [Related]
5. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.
Chong AS; Scuderi P; Grimes WJ; Hersh EM
J Immunol; 1989 Mar; 142(6):2133-9. PubMed ID: 2493506
[TBL] [Abstract][Full Text] [Related]
6. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
LeFor AT; Eisenthal A; Rosenberg SA
J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
[TBL] [Abstract][Full Text] [Related]
8. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claësson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
9. H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity.
Gorelik E; Gunji Y; Herberman RB
J Immunol; 1988 Mar; 140(6):2096-102. PubMed ID: 3126240
[TBL] [Abstract][Full Text] [Related]
10. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
[TBL] [Abstract][Full Text] [Related]
11. Decrease of lymphokine (interleukin-2)-activated killer activity in peripheral blood after administration of natural interferon-gamma.
Yanagawa H; Sone S; Okubo A; Fukuta K; Nishioka Y; Ogura T
Jpn J Clin Oncol; 1990 Dec; 20(4):356-63. PubMed ID: 2126575
[TBL] [Abstract][Full Text] [Related]
12. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
Itoh K; Tilden AB; Balch CM
J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
[TBL] [Abstract][Full Text] [Related]
13. Transfection of beta 2-microglobulin restores IFN-mediated protection from natural killer cell lysis in YAC-1 lymphoma variants.
Ljunggren HG; Sturmhöfel K; Wolpert E; Hämmerling GJ; Kärre K
J Immunol; 1990 Jul; 145(1):380-6. PubMed ID: 2113557
[TBL] [Abstract][Full Text] [Related]
14. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy.
Mier JW; Brandon EP; Libby P; Janicka MW; Aronson FR
J Immunol; 1989 Oct; 143(7):2407-14. PubMed ID: 2528594
[TBL] [Abstract][Full Text] [Related]
15. Interferon-gamma protects human endothelial cells from lymphokine-activated killer cell-mediated lysis.
Renkonen R; Ristimäki A; Häyry P
Eur J Immunol; 1988 Nov; 18(11):1839-42. PubMed ID: 3144455
[TBL] [Abstract][Full Text] [Related]
16. IFN-gamma treatment of K562 cells inhibits natural killer cell triggering and decreases the susceptibility to lysis by cytoplasmic granules from large granular lymphocytes.
Grönberg A; Ferm MT; Ng J; Reynolds CW; Ortaldo JR
J Immunol; 1988 Jun; 140(12):4397-402. PubMed ID: 3131433
[TBL] [Abstract][Full Text] [Related]
17. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
[TBL] [Abstract][Full Text] [Related]
18. Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue.
Donskov F; Basse PH; Hokland M
Nat Immun; 1996-1997; 15(2-3):134-46. PubMed ID: 9162263
[TBL] [Abstract][Full Text] [Related]
19. Interferon-induced increase in sensitivity of ovarian cancer targets to lysis by lymphokine-activated killer cells: selective effects on HER2/neu-overexpressing cells.
Fady C; Gardner AM; Gera JF; Lichtenstein A
Cancer Res; 1992 Feb; 52(4):764-9. PubMed ID: 1346583
[TBL] [Abstract][Full Text] [Related]
20. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]